Why Windtree Therapeutics (WINT) Stock Is Getting Hammered

Windtree Therapeutics Inc WINT shares are trading lower by 20% to $0.32 during Thursday’s session after the company announced it approved a 1-for-18 reverse stock split of its common stock.

This measure, effective April 19, 2024, aims to increase the market price per share, ensuring compliance with Nasdaq’s minimum bid price requirement. Each 18 shares will be converted into 1 share without altering the stock’s par value.

The split affects all shareholders proportionally and does not change their ownership percentage, with fractional shares rounded up.

See Also: Netflix Stock Is In The Spotlight Thursday: What’s Going On?

Should I Sell My WINT Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of Windtree Therapeutics have lost 87.55% year to date. This compares to the average annual return of -84.5%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Windtree Therapeutics stock currently has an RSI of 50.46, indicating neutral conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

According to data from Benzinga Pro, WINT has a 52-week high of and a 52-week low of